Health InsuranceCEL-SCI To Present Data From Multikine Clinical Trials At National Institutes Of Health (NIH), National Cancer Institute (NCI) Seminar Series
CEL-SCI Corporation (NYSE Amex: CVM), a late stage cancer immunotherapy company, announced that Dr. Eyal Talor, CEL-SCI"s Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI"s Clinical Center and the Center for Human Immunology, NERD (New Research and Development) Seminar Series, which will take place on Friday July 10, 2009 at the NIH"s Clinical Center located at the main NIH campus, on 9000 Rockville Pike, Bethesda, MD. The title of Dr. Talor"s presentation is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work".
In the presentation, Dr. Talor will discuss Multikine"s immunotherapy clinical program for cancer, the unique mechanism of action of Multikine (published in the Journal of Clinical Oncology) and the way Multikine imparts the patient"s own immune response with the ability to mount a robust anti-tumor immune response against his/her tumor. Dr. Talor will also discuss the clinical findings from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians and researchers in the field as a key to improving disease outcome in these patients.
Dr. Talor will also discuss the objectives of the collaborative study between the NIH, NCI under a current Material Transfer Agreement. This work is aimed at elucidating the tumor microenvironment changes, at the molecular level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH collaborative study will use samples collected from patients with advanced primary Head and Neck cancer (Oral Squamous Cell Carcinoma) during the impending Multikine Pivotal Global Phase III trial and these samples will be tested by the NIH, NCI using Genomic Microarray technology, developed at the NIH, NCI laboratories.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company"s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation"s SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CEL-SCI Corporation